HLB bioStep Co.,Ltd. (KOSDAQ:278650)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,150.00
+35.00 (1.12%)
At close: Jun 5, 2026
Market Cap54.22B -60.7%
Revenue (ttm)73.96B +22.9%
Net Income-19.28B
EPS-1,085.34
Shares Out 17.21M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,816
Open3,120.00
Previous Close3,115.00
Day's Range3,020.00 - 3,195.00
52-Week Range3,005.00 - 10,100.00
Beta-0.24
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was found... [Read more]

Industry Commercial Physical and Biological Research
Founded 2012
Employees 147
Stock Exchange KOSDAQ
Ticker Symbol 278650
Full Company Profile

Financial Performance

In 2025, HLB bioStep's revenue was 74.05 billion, an increase of 27.30% compared to the previous year's 58.17 billion. Losses were -18.96 billion, 121.4% more than in 2024.

Financial Statements